{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T07:13:14Z","timestamp":1789283594589,"version":"build-2803163510"},"publisher-location":"New York, NY","reference-count":30,"publisher":"Springer US","isbn-type":[{"value":"9781071654156","type":"print"},{"value":"9781071654163","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-5416-3_36","type":"book-chapter","created":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T06:26:07Z","timestamp":1789280767000},"page":"757-780","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of Freeze-Dried Formulations for Biopharmaceutical Drug Products Using a Design of Experiments Approach: A Case Study on Antibody-Drug Conjugates"],"prefix":"10.1007","author":[{"given":"Maite","family":"Harguindeguy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Hawe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Menzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"issue":"2","key":"36_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/abt\/tbaf005","volume":"8","author":"L Wen","year":"2025","unstructured":"Wen L, Zhang Y, Sun C, Wang SS, Gong Y, Jia C, Luo J (2025) Fundamental properties and principal areas of focus in antibody\u2013drug conjugates formulation development. Antib Ther 8(2):99\u2013110. https:\/\/doi.org\/10.1093\/abt\/tbaf005","journal-title":"Antib Ther"},{"key":"36_CR2","doi-asserted-by":"crossref","unstructured":"Jameel F, Hershenson S, Khan MA Martin-Moe S (eds) (2015) Quality by design for biopharmaceutical drug product development. In: AAPS advances in the pharmaceutical sciences series. Springer New York, New York, NY","DOI":"10.1007\/978-1-4939-2316-8"},{"key":"36_CR3","doi-asserted-by":"crossref","unstructured":"Beg S, Hasnain MS, Rahman M et al (2019) Introduction to quality by design (QbD): fundamentals, principles, and applications. In: Pharmaceutical quality by design: principles and applications, 1st edn. CCXLII. Academic Press, pp 1\u201317","DOI":"10.1016\/B978-0-12-815799-2.00001-0"},{"key":"36_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ijpharm.2012.08.033","volume":"438","author":"D Awotwe-Otoo","year":"2012","unstructured":"Awotwe-Otoo D, Agarabi C, Wu GK, Casey E, Read E, Lute S, Brorson KA, Khan MA, Shah RB (2012) Quality by design: impact of formulation variables and their interactions on quality attributes of a lyophilized monoclonal antibody. Int J Pharm 438:167\u2013175. https:\/\/doi.org\/10.1016\/j.ijpharm.2012.08.033","journal-title":"Int J Pharm"},{"key":"36_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05476-1","volume":"22","author":"A Ibnidris","year":"2024","unstructured":"Ibnidris A, Liaskos N, Eldem E, Gunn A, Streffer J, Gold M, Rea M, Teipel S, Gardiol A, Boccardi M (2024) Facilitating the use of the target product profile in academic research: a systematic review. J Transl Med 22: 693. https:\/\/doi.org\/10.1186\/s12967-024-05476-1","journal-title":"J Transl Med"},{"key":"36_CR6","first-page":"19","volume":"3","author":"Y Mehmood","year":"2015","unstructured":"Mehmood Y, Farooq U (2015) Excipients use in parenteral and lyophilized formulation development.. Open Sci J Pharm Pharmacol 3:19\u201327","journal-title":"Open Sci J Pharm Pharmacol"},{"key":"36_CR7","unstructured":"Szkudlarek BA (1997) Selective crystallization of phosphate buffer components and pH changes during freezing: implications to protein stability. Ph.D., University of Michigan"},{"key":"36_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0378-5173(00)00423-3","volume":"203","author":"W Wang","year":"2000","unstructured":"Wang W (2000) Lyophilization and development of solid protein pharmaceuticals. Int J Pharm 203:1\u201360. https:\/\/doi.org\/10.1016\/s0378-5173(00)00423-3","journal-title":"Int J Pharm"},{"key":"36_CR9","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40005-017-0341-9","volume":"47","author":"JG Song","year":"2017","unstructured":"Song JG, Lee SH, Han H-K (2017) The stabilization of biopharmaceuticals: current understanding and future perspectives. J Pharm Investig 47:475\u2013496. https:\/\/doi.org\/10.1007\/s40005-017-0341-9","journal-title":"J Pharm Investig"},{"key":"36_CR10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ijpharm.2019.02.019","volume":"560","author":"L Samuelsen","year":"2019","unstructured":"Samuelsen L, Holm R, Lathuile A, Sch\u00f6nbeck C (2019) Buffer solutions in drug formulation and processing: how pKa values depend on temperature, pressure and ionic strength. Int J Pharm 560:357\u2013364. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.02.019","journal-title":"Int J Pharm"},{"key":"36_CR11","unstructured":"Strickley RG, Katz JS, Schoneker DR (2021) Open scientific discussion: excipients in sterile products. AAPS Excipients and Sterile Products Communities"},{"key":"36_CR12","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1080\/03639045.2017.1278768","volume":"43","author":"Y Cui","year":"2017","unstructured":"Cui Y, Cui P, Chen B, Li S, Guan H (2017) Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system. Drug Dev Ind Pharm 43:519\u2013530. https:\/\/doi.org\/10.1080\/03639045.2017.1278768","journal-title":"Drug Dev Ind Pharm"},{"key":"36_CR13","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1023\/a:1012180707283","volume":"14","author":"JF Carpenter","year":"1997","unstructured":"Carpenter JF, Pikal MJ, Chang BS, Randolph TW (1997) Rational design of stable lyophilized protein formulations: some practical advice. Pharm Res 14:969\u2013975. https:\/\/doi.org\/10.1023\/a:1012180707283","journal-title":"Pharm Res"},{"key":"36_CR14","doi-asserted-by":"publisher","first-page":"115301","DOI":"10.1016\/j.addr.2024.115301","volume":"209","author":"N Mathias","year":"2024","unstructured":"Mathias N, Huille S, Picci M, Mahoney RP, Pettis RJ, Case B, Helk B, Kang D, Shah R, Ma J, Bhattacharya D, Krishnamachari Y, Doucet D, Maksimovikj N, Babaee S, Garidel P, Esfandiary R, Gandhi R (2024) Towards more tolerable subcutaneous administration: review of contributing factors for improving combination product design. Adv Drug Deliv Rev 209:115301. https:\/\/doi.org\/10.1016\/j.addr.2024.115301","journal-title":"Adv Drug Deliv Rev"},{"key":"36_CR15","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ejpb.2018.04.005","volume":"128","author":"A Arsiccio","year":"2018","unstructured":"Arsiccio A, Pisano R (2018) Surfactants as stabilizers for biopharmaceuticals: an insight into the molecular mechanisms for inhibition of protein aggregation. Eur J Pharm Biopharm 128:98\u2013106. https:\/\/doi.org\/10.1016\/j.ejpb.2018.04.005","journal-title":"Eur J Pharm Biopharm"},{"key":"36_CR16","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s11095-024-03726-x","volume":"41","author":"MC Manning","year":"2024","unstructured":"Manning MC, Holcomb RE, Payne RW, Stillahn JM, Connolly BD, Katayama DS, Liu H, Matsuura JE, Murphy BM, Henry CS, Crommelin DJA (2024) Stability of protein pharmaceuticals: recent advances. Pharm Res 41:1301\u20131367. https:\/\/doi.org\/10.1007\/s11095-024-03726-x","journal-title":"Pharm Res"},{"key":"36_CR17","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.xphs.2019.10.016","volume":"109","author":"C Haeuser","year":"2020","unstructured":"Haeuser C, Goldbach P, Huwyler J, Friess W, Allmendinger A (2020) Excipients for room temperature stable freeze-dried monoclonal antibody formulations. J Pharm Sci 109:807\u2013817. https:\/\/doi.org\/10.1016\/j.xphs.2019.10.016","journal-title":"J Pharm Sci"},{"key":"36_CR18","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1023\/A:1012164520429","volume":"14","author":"MJ Pikal","year":"1997","unstructured":"Pikal MJ, Rigsbee DR (1997) The stability of insulin in crystalline and amorphous solids: observation of greater stability for the amorphous form. Pharm Res 14:1379\u20131387","journal-title":"Pharm Res"},{"key":"36_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0939-6411(98)00004-6","volume":"45","author":"F Franks","year":"1998","unstructured":"Franks F (1998) Freeze-drying of bioproducts: putting principles into practice. Eur J Pharm Biopharm 45:221\u2013229. https:\/\/doi.org\/10.1016\/S0939-6411(98)00004-6","journal-title":"Eur J Pharm Biopharm"},{"key":"36_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1006\/cryo.1997.2020","volume":"35","author":"JH Crowe","year":"1997","unstructured":"Crowe JH, Oliver AE, Hoekstra FA, Crowe LM (1997) Stabilization of dry membranes by mixtures of hydroxyethyl starch and glucose: the role of vitrification. Cryobiology 35:20\u201330. https:\/\/doi.org\/10.1006\/cryo.1997.2020","journal-title":"Cryobiology"},{"key":"36_CR21","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/1520-6017(200103)90:3<310::AID-JPS6>3.0.CO;2-R","volume":"90","author":"JF Cleland","year":"2001","unstructured":"Cleland JF, Lam X, Kendrick B, Yang J, Yang TH, Overcashier D, Brooks D, Hsu C, Carpenter JF (2001) A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody. J Pharm Sci 90:310\u2013321","journal-title":"J Pharm Sci"},{"key":"36_CR22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1081\/PDT-200056308","volume":"10","author":"JJ Schwegman","year":"2005","unstructured":"Schwegman JJ, Hardwick L, Akers M (2005) Practical formulation and process development of freeze-dried products. Pharm Dev Tech 10:151\u2013173. https:\/\/doi.org\/10.1081\/PDT-200056308","journal-title":"Pharm Dev Tech"},{"key":"36_CR23","first-page":"41","volume":"1","author":"A Baheti","year":"2010","unstructured":"Baheti A, Bansal A (2010) Excipients used in lyophilization of small molecules. J Excip Food Chem 1:41\u201354","journal-title":"J Excip Food Chem"},{"key":"36_CR24","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/jps.10094","volume":"91","author":"RE Johnson","year":"2002","unstructured":"Johnson RE, Kirchhoff CF, Gaud HT (2002) Mannitol-sucrose mixtures\u2014versatile formulations for protein lyophilization. J Pharm Sci 91:914\u2013922. https:\/\/doi.org\/10.1002\/jps.10094","journal-title":"J Pharm Sci"},{"key":"36_CR25","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s11095-006-9158-3","volume":"24","author":"X Liao","year":"2007","unstructured":"Liao X, Krishnamurthy R, Suryanarayanan R (2007) Influence processing conditions on the physical state of mannitol\u2014implications in freeze drying. Pharm Res 24:370\u2013376","journal-title":"Pharm Res"},{"key":"36_CR26","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/abt\/tbad022","volume":"6","author":"S Ren","year":"2023","unstructured":"Ren S (2023) Effects of arginine in therapeutic protein formulations: a decade review and perspectives. Antib Ther 6:265\u2013276. https:\/\/doi.org\/10.1093\/abt\/tbad022","journal-title":"Antib Ther"},{"key":"36_CR27","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1006\/abbi.1998.0832","volume":"358","author":"SD Allison","year":"1998","unstructured":"Allison SD, Randolph TW, Manning MC, Middleton K, Davis A, Carpenter JF (1998) Effects of drying methods and additives on structure and function of actin: mechanisms of dehydration-induced damage and its inhibition. Arch Biochem Byophys 358:171\u2013181","journal-title":"Arch Biochem Byophys"},{"key":"36_CR28","doi-asserted-by":"publisher","first-page":"100180","DOI":"10.1016\/j.ijpx.2023.100180","volume":"5","author":"B Vanbillemont","year":"2023","unstructured":"Vanbillemont B, Greiner AL, Ehrl V, Menzen T, Friess W, Hawe A (2023) A model-based optimization strategy to achieve fast and robust freeze-drying cycles. Int J Pharm X 5:100180. https:\/\/doi.org\/10.1016\/j.ijpx.2023.100180","journal-title":"Int J Pharm X"},{"key":"36_CR29","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ejpb.2019.03.021","volume":"139","author":"C Duerr","year":"2019","unstructured":"Duerr C, Friess W (2019) Antibody-drug conjugates-stability and formulation. Eur J Pharm Biopharm 139:168\u2013176. https:\/\/doi.org\/10.1016\/j.ejpb.2019.03.021","journal-title":"Eur J Pharm Biopharm"},{"key":"36_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s41120-025-00115-5","volume":"11","author":"B Vanbillemont","year":"2025","unstructured":"Vanbillemont B, Greiner AL, Ehrl V, Menzen T, Friess W, Hawe A (2025) Optimization and transfer of robust primary drying protocols for biopharmaceuticals through lyophilization process modeling. AAPS Open 11: 4573. https:\/\/doi.org\/10.1186\/s41120-025-00115-5","journal-title":"AAPS Open"}],"container-title":["Methods in Molecular Biology","Cryopreservation and Freeze-Drying Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5416-3_36","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T06:26:09Z","timestamp":1789280769000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5416-3_36"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9781071654156","9781071654163"],"references-count":30,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5416-3_36","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"14 September 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}